Despite the unexpectedly rapid development of effective SARS-CoV-2 vaccines, we do not have effective orally available antivirals. This is particularly problematic due to vaccine hesitancy. The current best treatment options: Remdesivir and monoclonal antibodies, require intravenous injection in a hospital. I will discuss two studies identifying FDA-approved drugs active against SARS-CoV-2 in the laboratory setting and their underlying biology.
Dr. Glenn Randall received his B.S. with distinction in Microbiology from the University of Illinois, Urbana-Champaign. After an internship at Abbott Laboratories, he pursued graduate studies at The University of Chicago in the laboratory of Bernard Roizman. He then joined the Laboratory of Virology and Infectious Disease at Rockefeller University in New York. His American Cancer Society postdoctoral fellowship was under the mentorship of Charles Rice. He joined the Department of Microbiology at the University of Chicago in August of 2005. Dr. Randall has received numerous awards, including the Schweppe Fellowship, the American Liver Foundation Heman Lopata Hepatitis C Scholar, The University of Chicago DDRCC Outstanding New Investigator, a Career Development Award from the Great Lakes Center for Excellence (NIH/NAIAD) and an American Cancer Society Research Scholar Award. In 2020 he was appointed as the Director of Emerging Infection Research at the Howard Taylor Ricketts Regional Biocontainment Laboratory where he leads COVID-19 research.
Join via Zoom: https://stevens.zoom.us/j/98576021770